S100A16 and ovarian carcinoma: Analysis of a database with 1657 ovarian cancer patients showed that high expression of S100A2, S100A7A, S100A10, and S100A16 significantly correlated with worse overall survival (OS) in ovarian cancer patients, while the expression of S100A1, S100A3, S100A5, S100A6, and S100A13 were associated with better prognosis [27].